What question did this study set out to answer?

The study aims to understand how senescence-like tumor-associated macrophages affect chemoresistance in triple-negative breast cancer.

March 25, 2026Cellular OncologyOpen Access

Targeting senescence-like tumor-associated macrophages sensitizes chemotherapy in triple-negative breast cancer

View Full Paper

Ask AI

Bookmark

The study aims to understand how senescence-like tumor-associated macrophages affect chemoresistance in triple-negative breast cancer.
Used orthotopic TNBC models to study chemoresistance mechanisms.
Administered doxorubicin to induce senescence-like TAM phenotypes.
Combined senolytic agent ABT263 with IL-6 signaling blockade in vivo.
Performed multiplexed immunofluorescence on clinical TNBC samples.
Doxorubicin induced a senescence-like phenotype in TAMs confirmed by p16/p21 upregulation.
Senescence-like TAMs secreting IL-6 activated the IL-6R/STAT3 axis, increasing drug-resistance gene expression.
Targeting senescence-like TAMs restored chemosensitivity, enhancing the effectiveness of doxorubicin.
Senescence-like TAM accumulation in treated tumors correlated with progressive disease rather than therapeutic response.

Authors

No takes yet. Share an insight, caveat, or question.

Demonstrates that targeting macrophages improves chemotherapy response in triple-negative breast cancer, suggesting new treatment strategies.

Zhou et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Demonstrates that targeting macrophages improves chemotherapy response in triple-negative breast cancer, suggesting new treatment strategies.